Vanguard Group
EIDX

Vanguard Group’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

Vanguard Group’s Portfolio EIDX Stock Details EIDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-905,343
Closed -$119M – 4369
2020
Q4 		$119M Buy
905,343
+175,188
+24% +$15.5M ﹤0.01% 1746
2020
Q3 		$36.9M Buy
730,155
+34,903
+5% +$1.57M ﹤0.01% 2166
2020
Q2 		$33.1M Buy
695,252
+251,429
+57% +$11.7M ﹤0.01% 2198
2020
Q1 		$21.7M Buy
443,823
+41,682
+10% +$2.12M ﹤0.01% 2245
2019
Q4 		$23.1M Buy
402,141
+75,858
+23% +$3.76M ﹤0.01% 2463
2019
Q3 		$11.7M Sell
326,283
-49,895
-13% -$1.95M ﹤0.01% 2732
2019
Q2 		$11.7M Buy
376,178
+11,857
+3% +$321K ﹤0.01% 2774
2019
Q1 		$8.54M Buy
364,321
+108,720
+43% +$1.74M ﹤0.01% 2912
2018
Q4 		$3.52M Buy
255,601
+56,928
+29% +$718K ﹤0.01% 3203
2018
Q3 		$1.98M Buy
198,673
+148,673
+297% +$2.44M ﹤0.01% 3533
2018
Q2 		$1.02M Buy
+50,000
New +$1.05M ﹤0.01% 3682

Vanguard Group's EIDX Position: Q1 2021 in Review

Vanguard Group sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q1 2021, closing a stake of 905,343 shares — an estimated $119M sold.

Vanguard Group first reported a position in EIDX in Q2 2018 and held it in 11 quarters. The position peaked at $119M in Q4 2020. 0 funds tracked by Wall St. Rank hold EIDX as of Q1 2021.

  • Vanguard Group reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Vanguard Group sold 905,343 Eidos Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $119M.
  • Vanguard Group first reported a position in Eidos Therapeutics, Inc. Common Stock in Q2 2018 and held it in 11 quarters.
  • Vanguard Group's Eidos Therapeutics, Inc. Common Stock position peaked at $119M in Q4 2020.
  • 0 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Vanguard Group's 13F filing for Q1 2021, filed 14 May 2021.